Arrowhead Pharmaceuticals Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy ARWR?
Source: seekingalpha
- Earnings Beat: Arrowhead Pharmaceuticals reported a Q1 GAAP EPS of $0.22, surpassing expectations by $0.37, indicating strong profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $264.03 million, exceeding market expectations of $230.85 million, reflecting sustained demand for its products and further solidifying its market position.
- Stock Performance Volatility: Despite the earnings beat, Arrowhead's shares fell by 2%, indicating market caution regarding future growth, which may impact short-term investor sentiment.
- Expanded Financing Plans: Arrowhead upsized its convertible notes offering to $625 million and priced its stock offering at $64.50 per share, demonstrating a proactive approach to future expansion and R&D investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 62.380
Low
35.00
Averages
75.50
High
100.00
Current: 62.380
Low
35.00
Averages
75.50
High
100.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
Arrowhead Pharmaceuticals Q1 2026 Earnings Call Highlights
- FDA Approval of New Drug: Arrowhead received FDA approval and launched REDEMPLO in the U.S. for familial chylomicronemia syndrome, marking the company's first regulatory approval and initiating a new phase as a commercial entity, which is expected to drive revenue growth.
- Strong Financial Performance: For Q4 2025, net income was $30.8 million with earnings per share of $0.22, and total revenue reached $264 million, primarily driven by licensing and collaboration agreements with Sarepta and Novartis, showcasing the company's strong execution in the market.
- Successful Capital Raising: The company completed $1.33 billion in capital raising during the reporting period, including a $200 million upfront payment from Novartis and a $200 million milestone payment from Sarepta, providing robust funding support for future R&D and commercialization efforts.
- Optimistic Future Outlook: Management anticipates achieving positive cash flow through multiple independent and partnered product launches, emphasizing the commercial sales progress of REDEMPLO and upcoming key clinical data releases, indicating significant growth potential for the company in the coming years.
See More
Arrowhead Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Arrowhead Pharmaceuticals reported a Q1 GAAP EPS of $0.22, surpassing expectations by $0.37, indicating strong profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $264.03 million, exceeding market expectations of $230.85 million, reflecting sustained demand for its products and further solidifying its market position.
- Stock Performance Volatility: Despite the earnings beat, Arrowhead's shares fell by 2%, indicating market caution regarding future growth, which may impact short-term investor sentiment.
- Expanded Financing Plans: Arrowhead upsized its convertible notes offering to $625 million and priced its stock offering at $64.50 per share, demonstrating a proactive approach to future expansion and R&D investments.
See More
Arrowhead Pharmaceuticals Set to Announce Q1 Earnings on February 5th
- Earnings Announcement: Arrowhead Pharmaceuticals is set to release its Q1 earnings on February 5th after market close, with consensus EPS estimate at -$0.37 and revenue expected at $230.85 million, a significant increase from $2.5 million in Q1 FY2025, indicating potential revenue growth for the company.
- Historical Performance Review: Over the past two years, Arrowhead has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, reflecting uncertainty in financial performance that may impact investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced two upward revisions and four downward changes, suggesting market divergence regarding the company's future performance.
- Financing and Product Approval: Arrowhead recently upsized its convertible notes offering to $625 million and conducted a stock offering at $64.50 per share, while also gaining approval for Redemplo in China for high triglycerides, demonstrating positive progress in financing and product development.
See More
Privium Fund Management Reduces Arrowhead Holdings
- Share Reduction Details: Privium Fund Management disclosed in a February 2 SEC filing that it reduced its position in Arrowhead Pharmaceuticals by 75,747 shares in Q4, with an estimated trade value of $3.71 million, reflecting a risk management strategy.
- Position Value Surge: Despite the reduction, the value of Arrowhead in Privium's portfolio surged by $10.09 million at quarter-end, indicating a strong stock price increase of 289.5% year-over-year, significantly outperforming the S&P 500's 15% gain.
- Financial Performance: Arrowhead's fiscal 2025 revenue is projected to reach $829 million, a substantial increase from $3.6 million the previous year, primarily driven by licensing and milestone payments, showcasing accelerated commercialization efforts.
- Investor Confidence Signal: After the sale, Arrowhead still represents 4.87% of Privium's 13F U.S. equity AUM, indicating sustained confidence in Arrowhead while locking in some gains to manage market volatility within a high-risk portfolio.
See More
Privium Fund Management Sells Arrowhead Shares
- Sale Overview: Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals in Q4, with an estimated transaction value of $3.71 million, demonstrating the fund's agility in navigating market fluctuations.
- Position Value Increase: Despite the sale, Privium's position in Arrowhead increased by $10.09 million, reflecting the stock's robust price appreciation and indicating strong market confidence in the company's future prospects.
- Position Proportion Analysis: Following the transaction, Arrowhead represents 4.87% of Privium's 13F U.S. equity AUM, highlighting the fund's continued optimism towards the company even after partial divestment.
- Financial Performance Highlights: Arrowhead's fiscal 2025 revenue is projected to surge to $829 million from just $3.6 million last year, showcasing the success of its commercialization efforts and strong market demand.
See More
Casgevy Therapy Revenue Shows Significant Growth
- Revenue Growth: Casgevy gene-editing therapy generated $54 million in Q4 2025 and $116 million for the full year, indicating strong market demand and significant business growth potential.
- Increased Patient Treatments: A total of 147 patients initiated treatment in 2025, nearly tripling from 2024, with 30 infusions occurring in Q4, reflecting heightened acceptance and confidence in the therapy.
- Pipeline Advancement: The company continues to advance its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in the second half of 2026.
- Financial Position: CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, despite R&D expenses rising to $83.5 million in Q4 and net loss widening to $130.6 million, market confidence in its future growth remains strong.
See More
Arrowhead Pharmaceuticals Q1 2026 Earnings Call Highlights
- FDA Approval of New Drug: Arrowhead received FDA approval and launched REDEMPLO in the U.S. for familial chylomicronemia syndrome, marking the company's first regulatory approval and initiating a new phase as a commercial entity, which is expected to drive revenue growth.
- Strong Financial Performance: For Q4 2025, net income was $30.8 million with earnings per share of $0.22, and total revenue reached $264 million, primarily driven by licensing and collaboration agreements with Sarepta and Novartis, showcasing the company's strong execution in the market.
- Successful Capital Raising: The company completed $1.33 billion in capital raising during the reporting period, including a $200 million upfront payment from Novartis and a $200 million milestone payment from Sarepta, providing robust funding support for future R&D and commercialization efforts.
- Optimistic Future Outlook: Management anticipates achieving positive cash flow through multiple independent and partnered product launches, emphasizing the commercial sales progress of REDEMPLO and upcoming key clinical data releases, indicating significant growth potential for the company in the coming years.
See More
Arrowhead Pharmaceuticals Q1 Earnings Exceed Expectations
- Earnings Beat: Arrowhead Pharmaceuticals reported a Q1 GAAP EPS of $0.22, surpassing expectations by $0.37, indicating strong profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $264.03 million, exceeding market expectations of $230.85 million, reflecting sustained demand for its products and further solidifying its market position.
- Stock Performance Volatility: Despite the earnings beat, Arrowhead's shares fell by 2%, indicating market caution regarding future growth, which may impact short-term investor sentiment.
- Expanded Financing Plans: Arrowhead upsized its convertible notes offering to $625 million and priced its stock offering at $64.50 per share, demonstrating a proactive approach to future expansion and R&D investments.
See More
Arrowhead Pharmaceuticals Set to Announce Q1 Earnings on February 5th
- Earnings Announcement: Arrowhead Pharmaceuticals is set to release its Q1 earnings on February 5th after market close, with consensus EPS estimate at -$0.37 and revenue expected at $230.85 million, a significant increase from $2.5 million in Q1 FY2025, indicating potential revenue growth for the company.
- Historical Performance Review: Over the past two years, Arrowhead has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, reflecting uncertainty in financial performance that may impact investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced two upward revisions and four downward changes, suggesting market divergence regarding the company's future performance.
- Financing and Product Approval: Arrowhead recently upsized its convertible notes offering to $625 million and conducted a stock offering at $64.50 per share, while also gaining approval for Redemplo in China for high triglycerides, demonstrating positive progress in financing and product development.
See More
Privium Fund Management Reduces Arrowhead Holdings
- Share Reduction Details: Privium Fund Management disclosed in a February 2 SEC filing that it reduced its position in Arrowhead Pharmaceuticals by 75,747 shares in Q4, with an estimated trade value of $3.71 million, reflecting a risk management strategy.
- Position Value Surge: Despite the reduction, the value of Arrowhead in Privium's portfolio surged by $10.09 million at quarter-end, indicating a strong stock price increase of 289.5% year-over-year, significantly outperforming the S&P 500's 15% gain.
- Financial Performance: Arrowhead's fiscal 2025 revenue is projected to reach $829 million, a substantial increase from $3.6 million the previous year, primarily driven by licensing and milestone payments, showcasing accelerated commercialization efforts.
- Investor Confidence Signal: After the sale, Arrowhead still represents 4.87% of Privium's 13F U.S. equity AUM, indicating sustained confidence in Arrowhead while locking in some gains to manage market volatility within a high-risk portfolio.
See More
Privium Fund Management Sells Arrowhead Shares
- Sale Overview: Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals in Q4, with an estimated transaction value of $3.71 million, demonstrating the fund's agility in navigating market fluctuations.
- Position Value Increase: Despite the sale, Privium's position in Arrowhead increased by $10.09 million, reflecting the stock's robust price appreciation and indicating strong market confidence in the company's future prospects.
- Position Proportion Analysis: Following the transaction, Arrowhead represents 4.87% of Privium's 13F U.S. equity AUM, highlighting the fund's continued optimism towards the company even after partial divestment.
- Financial Performance Highlights: Arrowhead's fiscal 2025 revenue is projected to surge to $829 million from just $3.6 million last year, showcasing the success of its commercialization efforts and strong market demand.
See More
